People · Operator
Named in public records as an officer, director or promoter · active 2018–2024 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Endeavor Biomedicines, Inc. | — | Biotechnology | Series D+ | $221.7M | $1.6B | 2024 |
| Vineti, Inc. | — | Biotechnology | Series C | $115.7M | $2.8B | 2018 |
| Strateos, Inc. | — | Other Technology | Series B | $16.5M | $502.5M | 2019 |
Chris Krueger at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Chris Krueger on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Nina Kjellson | 1 | 11 |
| Emily Melton | 1 | 10 |
| Risa Stack | 1 | 9 |
| Patrick G. Enright | 1 | 7 |
| Rowan Chapman | 1 | 7 |
| Eli Casdin | 1 | 6 |
| Armen Vidian | 1 | 5 |
| Michael Pellini | 1 | 4 |
| Joshua Wolfe | 1 | 4 |
| BERNARD DAVITIAN | 1 | 4 |
| Miguel De Los Rios | 1 | 3 |
| Mara Aspinall | 1 | 3 |
| John Kontor | 1 | 2 |
| Amy DuRoss | 1 | 2 |
| Joseph DePinto | 1 | 2 |
| Mark Fischer-Colbrie | 1 | 2 |
| Jeff Finer | 1 | 1 |
| John Hood | 1 | 1 |
| Vishaal Turakhia | 1 | 1 |
| Enoch Kariuki | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.